 | • レポートコード：MRC2Q12-19317 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥710,500 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,421,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、PD-1/PD-L1阻害剤のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 PD-1/PD-L1阻害剤のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 PD-1/PD-L1阻害剤の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 PD-1/PD-L1阻害剤のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのPD-1/PD-L1阻害剤の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のPD-1/PD-L1阻害剤の売上および2028年までの予測に焦点を当てています。 PD-1/PD-L1阻害剤のグローバル主要企業には、Merck、Bristol-Myers Squibb、Pfizer、Sanofi、Regeneron Pharmaceuticals、Roche、AstraZeneca、Bristol Myers Squibb、Hengrui Medicine、Beigene、Innovent Biologics、Junshi Biosciences、Akeso、Alphamab Oncologyなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 PD-1/PD-L1阻害剤市場は、タイプとアプリケーションによって区分されます。世界のPD-1/PD-L1阻害剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 モノクローナル抗体、バイスペシフィック抗体 【アプリケーション別セグメント】 肺がん、胃がん、乳がん、直腸がん、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - PD-1/PD-L1阻害剤製品概要 - タイプ別市場（モノクローナル抗体、バイスペシフィック抗体） - アプリケーション別市場（肺がん、胃がん、乳がん、直腸がん、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のPD-1/PD-L1阻害剤販売量予測2017-2028 - 世界のPD-1/PD-L1阻害剤売上予測2017-2028 - PD-1/PD-L1阻害剤の地域別販売量 - PD-1/PD-L1阻害剤の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別PD-1/PD-L1阻害剤販売量 - 主要メーカー別PD-1/PD-L1阻害剤売上 - 主要メーカー別PD-1/PD-L1阻害剤価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（モノクローナル抗体、バイスペシフィック抗体） - PD-1/PD-L1阻害剤のタイプ別販売量 - PD-1/PD-L1阻害剤のタイプ別売上 - PD-1/PD-L1阻害剤のタイプ別価格 ・アプリケーション別市場規模（肺がん、胃がん、乳がん、直腸がん、その他） - PD-1/PD-L1阻害剤のアプリケーション別販売量 - PD-1/PD-L1阻害剤のアプリケーション別売上 - PD-1/PD-L1阻害剤のアプリケーション別価格 ・北米市場 - 北米のPD-1/PD-L1阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のPD-1/PD-L1阻害剤市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのPD-1/PD-L1阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のPD-1/PD-L1阻害剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のPD-1/PD-L1阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のPD-1/PD-L1阻害剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のPD-1/PD-L1阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のPD-1/PD-L1阻害剤市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのPD-1/PD-L1阻害剤市場規模（タイプ別、アプリケーション別） - 主要国別のPD-1/PD-L1阻害剤市場規模（トルコ、サウジアラビア） ・企業情報 Merck、Bristol-Myers Squibb、Pfizer、Sanofi、Regeneron Pharmaceuticals、Roche、AstraZeneca、Bristol Myers Squibb、Hengrui Medicine、Beigene、Innovent Biologics、Junshi Biosciences、Akeso、Alphamab Oncology ・産業チェーン及び販売チャネル分析 - PD-1/PD-L1阻害剤の産業チェーン分析 - PD-1/PD-L1阻害剤の原材料 - PD-1/PD-L1阻害剤の生産プロセス - PD-1/PD-L1阻害剤の販売及びマーケティング - PD-1/PD-L1阻害剤の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - PD-1/PD-L1阻害剤の産業動向 - PD-1/PD-L1阻害剤のマーケットドライバー - PD-1/PD-L1阻害剤の課題 - PD-1/PD-L1阻害剤の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of PD-1 and PD-L1 Inhibitor include Merck, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron Pharmaceuticals, Roche, AstraZeneca, Bristol Myers Squibb and Hengrui Medicine, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the PD-1 and PD-L1 Inhibitor manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional PD-1 and PD-L1 Inhibitor market. Further, it explains the major drivers and regional dynamics of the global PD-1 and PD-L1 Inhibitor market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Merck
Bristol-Myers Squibb
Pfizer
Sanofi
Regeneron Pharmaceuticals
Roche
AstraZeneca
Bristol Myers Squibb
Hengrui Medicine
Beigene
Innovent Biologics
Junshi Biosciences
Akeso
Alphamab Oncology
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
PD-1 and PD-L1 Inhibitor Segment by Type
Monoclonal Antibody
Bispecific Antibody
PD-1 and PD-L1 Inhibitor Segment by Application
Lung Cancer
Stomach Cancer
Breast Cancer
Rectal Cancer
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the PD-1 and PD-L1 Inhibitor market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for PD-1 and PD-L1 Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of PD-1 and PD-L1 Inhibitor, also provides the sales of main regions and countries. Highlights of the upcoming market potential for PD-1 and PD-L1 Inhibitor, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PD-1 and PD-L1 Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global PD-1 and PD-L1 Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for PD-1 and PD-L1 Inhibitor sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Merck, Bristol-Myers Squibb, Pfizer, Sanofi, Regeneron Pharmaceuticals, Roche, AstraZeneca, Bristol Myers Squibb and Hengrui Medicine, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of PD-1 and PD-L1 Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-1 and PD-L1 Inhibitor sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 PD-1 and PD-L1 Inhibitor Product Introduction
1.2 Market by Type
1.2.1 Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Monoclonal Antibody
1.2.3 Bispecific Antibody
1.3 Market by Application
1.3.1 Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Lung Cancer
1.3.3 Stomach Cancer
1.3.4 Breast Cancer
1.3.5 Rectal Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global PD-1 and PD-L1 Inhibitor Sales Estimates and Forecasts 2017-2028
2.2 Global PD-1 and PD-L1 Inhibitor Revenue Estimates and Forecasts 2017-2028
2.3 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global PD-1 and PD-L1 Inhibitor Sales by Region
2.4.1 Global PD-1 and PD-L1 Inhibitor Sales by Region (2017-2022)
2.4.2 Global Sales PD-1 and PD-L1 Inhibitor by Region (2023-2028)
2.5 Global PD-1 and PD-L1 Inhibitor Revenue by Region
2.5.1 Global PD-1 and PD-L1 Inhibitor Revenue by Region (2017-2022)
2.5.2 Global PD-1 and PD-L1 Inhibitor Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global PD-1 and PD-L1 Inhibitor Sales by Manufacturers
3.1.1 Global Top PD-1 and PD-L1 Inhibitor Manufacturers by Sales (2017-2022)
3.1.2 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of PD-1 and PD-L1 Inhibitor in 2021
3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers
3.2.1 Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers (2017-2022)
3.2.2 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitor Revenue in 2021
3.3 Global PD-1 and PD-L1 Inhibitor Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global PD-1 and PD-L1 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global PD-1 and PD-L1 Inhibitor Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global PD-1 and PD-L1 Inhibitor Sales by Type
4.1.1 Global PD-1 and PD-L1 Inhibitor Historical Sales by Type (2017-2022)
4.1.2 Global PD-1 and PD-L1 Inhibitor Forecasted Sales by Type (2023-2028)
4.1.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2017-2028)
4.2 Global PD-1 and PD-L1 Inhibitor Revenue by Type
4.2.1 Global PD-1 and PD-L1 Inhibitor Historical Revenue by Type (2017-2022)
4.2.2 Global PD-1 and PD-L1 Inhibitor Forecasted Revenue by Type (2023-2028)
4.2.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2017-2028)
4.3 Global PD-1 and PD-L1 Inhibitor Price by Type
4.3.1 Global PD-1 and PD-L1 Inhibitor Price by Type (2017-2022)
4.3.2 Global PD-1 and PD-L1 Inhibitor Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global PD-1 and PD-L1 Inhibitor Sales by Application
5.1.1 Global PD-1 and PD-L1 Inhibitor Historical Sales by Application (2017-2022)
5.1.2 Global PD-1 and PD-L1 Inhibitor Forecasted Sales by Application (2023-2028)
5.1.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2017-2028)
5.2 Global PD-1 and PD-L1 Inhibitor Revenue by Application
5.2.1 Global PD-1 and PD-L1 Inhibitor Historical Revenue by Application (2017-2022)
5.2.2 Global PD-1 and PD-L1 Inhibitor Forecasted Revenue by Application (2023-2028)
5.2.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2017-2028)
5.3 Global PD-1 and PD-L1 Inhibitor Price by Application
5.3.1 Global PD-1 and PD-L1 Inhibitor Price by Application (2017-2022)
5.3.2 Global PD-1 and PD-L1 Inhibitor Price Forecast by Application (2023-2028)
6 North America
6.1 North America PD-1 and PD-L1 Inhibitor Market Size by Type
6.1.1 North America PD-1 and PD-L1 Inhibitor Sales by Type (2017-2028)
6.1.2 North America PD-1 and PD-L1 Inhibitor Revenue by Type (2017-2028)
6.2 North America PD-1 and PD-L1 Inhibitor Market Size by Application
6.2.1 North America PD-1 and PD-L1 Inhibitor Sales by Application (2017-2028)
6.2.2 North America PD-1 and PD-L1 Inhibitor Revenue by Application (2017-2028)
6.3 North America PD-1 and PD-L1 Inhibitor Market Size by Country
6.3.1 North America PD-1 and PD-L1 Inhibitor Sales by Country (2017-2028)
6.3.2 North America PD-1 and PD-L1 Inhibitor Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe PD-1 and PD-L1 Inhibitor Market Size by Type
7.1.1 Europe PD-1 and PD-L1 Inhibitor Sales by Type (2017-2028)
7.1.2 Europe PD-1 and PD-L1 Inhibitor Revenue by Type (2017-2028)
7.2 Europe PD-1 and PD-L1 Inhibitor Market Size by Application
7.2.1 Europe PD-1 and PD-L1 Inhibitor Sales by Application (2017-2028)
7.2.2 Europe PD-1 and PD-L1 Inhibitor Revenue by Application (2017-2028)
7.3 Europe PD-1 and PD-L1 Inhibitor Market Size by Country
7.3.1 Europe PD-1 and PD-L1 Inhibitor Sales by Country (2017-2028)
7.3.2 Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific PD-1 and PD-L1 Inhibitor Market Size by Type
8.1.1 Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Type (2017-2028)
8.1.2 Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Type (2017-2028)
8.2 Asia Pacific PD-1 and PD-L1 Inhibitor Market Size by Application
8.2.1 Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Application (2017-2028)
8.2.2 Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Application (2017-2028)
8.3 Asia Pacific PD-1 and PD-L1 Inhibitor Market Size by Region
8.3.1 Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Region (2017-2028)
8.3.2 Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America PD-1 and PD-L1 Inhibitor Market Size by Type
9.1.1 Latin America PD-1 and PD-L1 Inhibitor Sales by Type (2017-2028)
9.1.2 Latin America PD-1 and PD-L1 Inhibitor Revenue by Type (2017-2028)
9.2 Latin America PD-1 and PD-L1 Inhibitor Market Size by Application
9.2.1 Latin America PD-1 and PD-L1 Inhibitor Sales by Application (2017-2028)
9.2.2 Latin America PD-1 and PD-L1 Inhibitor Revenue by Application (2017-2028)
9.3 Latin America PD-1 and PD-L1 Inhibitor Market Size by Country
9.3.1 Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2017-2028)
9.3.2 Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Type
10.1.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Type (2017-2028)
10.1.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Type (2017-2028)
10.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Application
10.2.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Application (2017-2028)
10.2.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Application (2017-2028)
10.3 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Country
10.3.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2017-2028)
10.3.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Overview
11.1.3 Merck PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Merck PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck Recent Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Corporation Information
11.2.2 Bristol-Myers Squibb Overview
11.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bristol-Myers Squibb Recent Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Overview
11.3.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Pfizer PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer Recent Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Overview
11.4.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Sanofi PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sanofi Recent Developments
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Corporation Information
11.5.2 Regeneron Pharmaceuticals Overview
11.5.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Regeneron Pharmaceuticals Recent Developments
11.6 Roche
11.6.1 Roche Corporation Information
11.6.2 Roche Overview
11.6.3 Roche PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Roche PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Roche Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Corporation Information
11.7.2 AstraZeneca Overview
11.7.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 AstraZeneca Recent Developments
11.8 Bristol Myers Squibb
11.8.1 Bristol Myers Squibb Corporation Information
11.8.2 Bristol Myers Squibb Overview
11.8.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Bristol Myers Squibb Recent Developments
11.9 Hengrui Medicine
11.9.1 Hengrui Medicine Corporation Information
11.9.2 Hengrui Medicine Overview
11.9.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Hengrui Medicine Recent Developments
11.10 Beigene
11.10.1 Beigene Corporation Information
11.10.2 Beigene Overview
11.10.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Beigene PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Beigene Recent Developments
11.11 Innovent Biologics
11.11.1 Innovent Biologics Corporation Information
11.11.2 Innovent Biologics Overview
11.11.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Innovent Biologics Recent Developments
11.12 Junshi Biosciences
11.12.1 Junshi Biosciences Corporation Information
11.12.2 Junshi Biosciences Overview
11.12.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Junshi Biosciences Recent Developments
11.13 Akeso
11.13.1 Akeso Corporation Information
11.13.2 Akeso Overview
11.13.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Akeso PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Akeso Recent Developments
11.14 Alphamab Oncology
11.14.1 Alphamab Oncology Corporation Information
11.14.2 Alphamab Oncology Overview
11.14.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Alphamab Oncology Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 PD-1 and PD-L1 Inhibitor Industry Chain Analysis
12.2 PD-1 and PD-L1 Inhibitor Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 PD-1 and PD-L1 Inhibitor Production Mode & Process
12.4 PD-1 and PD-L1 Inhibitor Sales and Marketing
12.4.1 PD-1 and PD-L1 Inhibitor Sales Channels
12.4.2 PD-1 and PD-L1 Inhibitor Distributors
12.5 PD-1 and PD-L1 Inhibitor Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 PD-1 and PD-L1 Inhibitor Industry Trends
13.2 PD-1 and PD-L1 Inhibitor Market Drivers
13.3 PD-1 and PD-L1 Inhibitor Market Challenges
13.4 PD-1 and PD-L1 Inhibitor Market Restraints
14 Key Findings in The Global PD-1 and PD-L1 Inhibitor Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
| 【PD-1/PD-L1阻害剤について】 PD-1/PD-L1阻害剤は、がん免疫療法において重要な役割を果たす薬剤です。これらの薬剤は、PD-1（Programmed Cell Death Protein 1）またはPD-L1（Programmed Cell Death Ligand 1）という免疫チェックポイントを標的としており、がん細胞が免疫系からの攻撃を回避するメカニズムを逆転させることによって、体内の免疫応答を強化します。 PD-1は、主にT細胞上に存在する受容体であり、免疫応答の調節に関与しています。免疫系は、異物やがん細胞を攻撃するために活性化されますが、過度の免疫応答は自己免疫疾患を引き起こす可能性があります。したがって、体は免疫応答を抑制するメカニズムを持っています。PD-1がその一例であり、PD-L1と結合することでT細胞の活性を抑制し、免疫応答を低下させます。がん細胞はこのメカニズムを利用して、T細胞からの攻撃を回避します。 PD-1/PD-L1阻害剤は、PD-1またはPD-L1の結合を阻害することにより、T細胞の活性化を促進します。これにより、体内の免疫系ががん細胞を認識し、攻撃することが可能になります。具体的には、PD-1阻害剤としてはニボルマブやペムブロリズマブがあり、PD-L1阻害剤にはアテゾリズマブやデュルバルマブなどがあります。 これらの薬剤は、さまざまながんに対して適応があり、特にメラノーマ、非小細胞肺がん、腎細胞がん、膀胱がん、頭頸部がんなどの治療に用いられています。これらのがんは、免疫抑制のメカニズムを活用して成長するため、PD-1/PD-L1阻害剤による治療が特に有効であることが示されています。たとえば、メラノーマ患者におけるPD-1阻害剤の使用は、従来の化学療法に比べて生存率を大幅に向上させる結果をもたらしています。 PD-1/PD-L1阻害剤の大きな特徴は、副作用のプロファイルです。従来の化学療法や放射線療法に比べて、これらの薬剤は一般的に副作用が少なく、患者に対する負担を軽減することができます。しかし、一方で、免疫関連の副作用として自己免疫症状が現れることもあります。これには、皮膚、内分泌器官、肺、腸などの臓器に対する免疫反応が含まれます。したがって、PD-1/PD-L1阻害剤の治療中は、医師による適切な監視が必要です。 さらに、PD-1/PD-L1阻害剤の効果に個人差があることも注目されています。治療を受ける患者の腫瘍マイクロ環境や遺伝的背景により、反応性が異なることがあります。このため、バイオマーカーの研究が進められており、特にPD-L1発現量やミスマッチ修復欠損（dMMR）などが、治療効果の予測因子として注目されています。これに基づいて、個別化医療の観点から、より効果的な治療戦略の構築が期待されています。 近年では、PD-1/PD-L1阻害剤と他の治療法との併用療法も注目されています。たとえば、化学療法や放射線療法、他の免疫療法（例えばCTLA-4阻害剤）との併用は、相乗効果を発揮する可能性があります。このように、多角的にアプローチすることによって、治療効果の向上が期待されます。 PD-1/PD-L1阻害剤の開発は、がん治療の新たなパラダイムシフトをもたらしました。これまで治療が難しかった進行がん患者に対しても、新しい治療の選択肢を提供することができるようになりました。また、これにより免疫療法が進化し、今後のがん治療における重要な戦略とされるでしょう。 最後に、PD-1/PD-L1阻害剤はがん治療において高い可能性を持つも、すべての患者に効果があるわけではありません。今後は、さらなる研究と臨床試験を通じて、反応性を予測するためのバイオマーカーの特定と、個別化医療の確立が求められます。これにより、より多くの患者がこの治療の恩恵を受けることができるようになることが期待されています。加えて、他の新しい免疫チェックポイント阻害剤の開発や、がんに対する新しい治療戦略の確立が進んでいくことで、がん治療の未来は明るいものになるでしょう。 |